269 related articles for article (PubMed ID: 29409313)
1. The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era.
Jin YN; Zhang WJ; Cai XY; Li MS; Lawrence WR; Wang SY; Mai DM; Du YY; Luo DH; Mo HY
Cancer Res Treat; 2019 Jan; 51(1):34-42. PubMed ID: 29409313
[TBL] [Abstract][Full Text] [Related]
2. Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis.
Chen J; Ding J; Xu Y; Hong H; Lin X; Xu M; Yan L; Xu T; Fei Z; Chen C
J Geriatr Oncol; 2023 Nov; 14(8):101648. PubMed ID: 37897887
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
[TBL] [Abstract][Full Text] [Related]
4. Impact of comorbidity on tolerability and survival following curative intent intensity modulated radiotherapy in older patients with nasopharyngeal cancer.
Sommat K; Yit NLF; Wang F; Lim JHC
J Geriatr Oncol; 2018 Jul; 9(4):352-358. PubMed ID: 29429963
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and prognosis of elderly nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy.
Lyu Y; Ni M; Zhai R; Kong F; Du C; Hu C; Ying H
Eur Arch Otorhinolaryngol; 2021 Jul; 278(7):2549-2557. PubMed ID: 33021689
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes and toxicity profiles among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) versus IMRT + carbon-ion radiotherapy: A propensity score-matched analysis.
Li Y; Guan X; Xing X; Hu C
Head Neck; 2024 Jul; 46(7):1766-1776. PubMed ID: 38591178
[TBL] [Abstract][Full Text] [Related]
8. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
[TBL] [Abstract][Full Text] [Related]
11. Stage-dependent conditional survival and failure hazard of non-metastatic nasopharyngeal carcinoma after intensity-modulated radiation therapy: Clinical implications for treatment strategies and surveillance.
Wang J; Huang X; Sun S; Wang K; Qu Y; Chen X; Wu R; Zhang Y; Liu Q; Zhang J; Luo J; Xiao J; Gao L; Xu G; Hu C; Li YX; Yi J
Cancer Med; 2021 Jun; 10(11):3613-3621. PubMed ID: 33960136
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiotherapy for elderly patients with nasopharyngeal carcinoma.
Cao C; Hu Q; Chen X
Head Neck; 2018 Mar; 40(3):590-595. PubMed ID: 29155480
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era.
Niu X; Xue F; Liu P; Hu C; He X
Int J Med Sci; 2022; 19(2):267-273. PubMed ID: 35165512
[No Abstract] [Full Text] [Related]
14. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
[TBL] [Abstract][Full Text] [Related]
15. Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study.
Liu F; Luo T; Jin T; Zhang J; Xiang Z; Yan R; Xie L; Wu X; Zhang H; Wang F; Li P; Liu L
BMC Cancer; 2019 Jun; 19(1):554. PubMed ID: 31176358
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
Yao JJ; Qi ZY; Liu ZG; Jiang GM; Xu XW; Chen SY; Zhu FT; Zhang WJ; Lawrence WR; Ma J; Zhou GQ; Sun Y
Radiother Oncol; 2019 Aug; 137():137-144. PubMed ID: 31102988
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of the ratio of neutrophils to lymphocytes before and after intensity modulated radiotherapy for patients with nasopharyngeal carcinoma.
Liu J; Wei C; Tang H; Liu Y; Liu W; Lin C
Medicine (Baltimore); 2020 Jan; 99(2):e18545. PubMed ID: 31914029
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma.
Hu J; Huang Q; Gao J; Guan X; Hu W; Yang J; Qiu X; Chen M; Kong L; Lu JJ
Cancer; 2020 Dec; 126(23):5173-5183. PubMed ID: 32931035
[TBL] [Abstract][Full Text] [Related]
19. Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis.
Huang XD; Zhou GQ; Lv JW; Zhou HQ; Zhong CW; Wu CF; Zheng ZQ; He XJ; Peng L; Ma J; Sun Y
Radiother Oncol; 2018 Nov; 129(2):389-395. PubMed ID: 30270098
[TBL] [Abstract][Full Text] [Related]
20. Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa.
Huang CL; Guo R; Li JY; Xu C; Mao YP; Tian L; Lin AH; Sun Y; Ma J; Tang LL
Eur Radiol; 2020 Feb; 30(2):816-822. PubMed ID: 31650266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
